NuCana PLC（NCNA）股票分析NCNANuCana PLC

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

NuCana PLC (NCNA) is a good buy right now, primarily due to its recent price momentum and technical indicators. The stock has seen a 5-day change of +15.79% and a 20-day change of +33.33%, indicating strong short-term performance. Furthermore, the RSI is at 77.736, suggesting that while the stock is nearing overbought territory, it still has momentum. However, the main risk is its negative earnings per share (EPS) of -0.99 reported in the last earnings, which reflects ongoing profitability challenges.

4 analysts cover NCNA: 4 rate it Buy, 0 Hold and 0 Sell.